The two BTDs that were granted for NASH were after phase 2b. Our NASH trial was a small phase 2 as proof of concept. There was no multiple dosage levels. The 350mg arm was open label and the FDA may accept that and not make us do a phase 2b/3 instead of just a phase 3 or they may not. Regardless of that if major improvement is seen in 700mg that should satisfy all requirements for a BTD and it should be filed once the analysis is done.